Diets high in resistant starch increase plasma levels of trimethylamine-N-oxide, a gut microbiome metabolite associated with CVD risk
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Production of trimethylamine-N-oxide (TMAO), a biomarker of CVD risk, is dependent on intestinal microbiota, but little is known of dietary conditions promoting changes in gut microbial communities. Resistant starches (RS) alter the human microbiota. We sought to determine whether diets varying in RS and carbohydrate (CHO) content affect plasma TMAO levels. We also assessed postprandial glucose and insulin responses and plasma lipid changes to diets high and low in RS. In a cross-over trial, fifty-two men and women consumed a 2-week baseline diet (41 percentage of energy (%E) CHO, 40 % fat, 19 % protein), followed by 2-week high- and low-RS diets separated by 2-week washouts. RS diets were assigned at random within the context of higher (51–53 %E)v. lower CHO (39–40 %E) intake. Measurements were obtained in the fasting state and, for glucose and insulin, during a meal test matching the composition of the assigned diet. With lower CHO intake, plasma TMAO, carnitine, betaine and γ-butyrobetaine concentrations were higher after the high-v. low-RS diet (P<0·01 each). These metabolites were not differentially affected by high v. low RS when CHO intake was high. Although the high-RS meal reduced postprandial insulin and glucose responses when CHO intake was low (P<0·01 each), RS did not affect fasting lipids, lipoproteins, glucose or insulin irrespective of dietary CHO content. In conclusion, a lower-CHO diet high in RS was associated with higher plasma TMAO levels. These findings, together with the absence of change in fasting lipids, suggest that short-term high-RS diets do not improve markers of cardiometabolic health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · cited 6×
“and human studies have shown that gut microbial metabolism of dietary trimethylamines produces trimethylamine-N-oxide (TMAO), a metabolite associated with risk of CVD, independent of traditional CVD risk factors((1,2,4)).”
BackgroundSelf-citationIntestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Self-citationIntestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Self-citationGut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.011 · Cited by 1,968
Self-citationDominant and diet-responsive groups of bacteria within the human colonic microbiota
Walker, A. W., Ince, J., Duncan, S. H., Webster, L. M., Holtrop, G., Ze, X., Brown, D., Stares, M. D., Scott, P., Bergerat, A., et al. (2011) · The ISME Journal · doi:10.1038/ismej.2010.118 · Cited by 1,632
Wang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.055 · Cited by 1,317 · cited 2×
“Notably, in a susceptible mouse model, inhibition of microbial trimethylamine production from choline was recently shown to reduce plasma levels of TMAO and to inhibit the development of atherosclerotic lesions((13)).”
BackgroundSelf-citationBennett, B. J., Vallim, T. Q. D. A., Wang, Z., Shih, D. M., Meng, Y., Gregory, J., Allayee, H., Lee, R., Graham, M., Crooke, R., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.011 · Cited by 1,070 · cited 1×
“Trimethylamine is then absorbed and rapidly oxidised to TMAO by hepatic flavin monooxygenases((31)).”
BackgroundSelf-citationSeldin, M. M., Meng, Y., Qi, H., Zhu, W., Wang, Z., Hazen, S. L., Lusis, A. J., & Shih, D. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002767 · Cited by 911 · cited 1×
“activation of arterial endothelial cells((32)), and through a direct effect on intracellular Ca signalling in platelets, promoting a prothrombotic phenotype((33)).”
BackgroundSelf-citationRomano, K. A., Vivas, E. I., Amador-Noguez, D., & Rey, F. E. (2015) · mBio · doi:10.1128/mbio.02481-14 · Cited by 777 · cited 1×
“One recent study examined seventy-nine human microbial isolates spanning several common phyla observed in the human gut and identified several human commensals with TMA-producing activity((40)).”
BackgroundMicrobial conversion of choline to trimethylamine requires a glycyl radical enzyme
Craciun, S., & Balskus, E. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215689109 · Cited by 701
Martínez, I., Kim, J., Duffy, P. R., Schlegel, V. L., & Walter, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015046 · Cited by 645
Wang, Z., Tang, W. H. W., Buffa, J. A., Fu, X., Britt, E. B., Koeth, R. A., Levison, B. S., Fan, Y., Wu, Y., & Hazen, S. L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu002 · Cited by 559 · cited 1×
“Studies from this group have also established that elevated plasma levels of carnitine, choline and betaine are associated with CVD risk because of their role in formation of TMAO((1,2,5)).”
BackgroundSelf-citationγ-Butyrobetaine Is a Proatherogenic Intermediate in Gut Microbial Metabolism of L-Carnitine to TMAO
Koeth, R. A., Levison, B. S., Culley, M. K., Buffa, J. A., Wang, Z., Gregory, J. C., Org, E., Wu, Y., Li, L., Smith, J. D., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.006 · Cited by 546 · cited 1×
“More recently, another precursor of TMAO, γ-butyrobetaine, was shown to be associated with the development of atherosclerosis in a susceptible mouse model((3)).”
BackgroundSelf-citationRobertson, M. D., Bickerton, A. S., Dennis, A. L., Vidal, H., & Frayn, K. N. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.3.559 · Cited by 501
Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota
Zhu, Y., Jameson, E., Crosatti, M., Schäfer, H., Rajakumar, K., Bugg, T. D. H., & Chen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316569111 · Cited by 372 · cited 1×
“Although recent studies have delineated biochemical processes involved in the microbial conversion of choline and carnitine to TMAO((38,39)), little is known of the diversity of microbial taxa that can contribute to this process.”
BackgroundFlavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Miao, J., Ling, A. V., Manthena, P. V., Gearing, M. E., Graham, M. J., Crooke, R. M., Croce, K. J., Esquejo, R. M., Clish, C. B., Morbid Obesity Study Group, et al. (2015) · Nature Communications · doi:10.1038/ncomms7498 · Cited by 368 · cited 1×
“Moreover, in two different mouse models of atherosclerosis, anti-sense oligonucleotide targeting of hepatic flavin monooxygenase 3 has been shown to similarly inhibit TMAO formation and development of atherosclerosis((34,35)).”
BackgroundShih, D. M., Wang, Z., Lee, R., Meng, Y., Che, N., Charugundla, S., Qi, H., Wu, J., Pan, C., Brown, J. M., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m051680 · Cited by 335 · cited 1×
“Moreover, in two different mouse models of atherosclerosis, anti-sense oligonucleotide targeting of hepatic flavin monooxygenase 3 has been shown to similarly inhibit TMAO formation and development of atherosclerosis((34,35)).”
BackgroundSelf-citationSeparate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia
Krauss, R. M., Blanche, P. J., Rawlings, R. S., Fernstrom, H. S., & Williams, P. T. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.5.1025 · Cited by 321
Self-citationWang, Z., Levison, B. S., Hazen, J. E., Donahue, L., Li, X.-M., & Hazen, S. L. (2014) · Analytical Biochemistry · doi:10.1016/j.ab.2014.03.016 · Cited by 320
Self-citationMiller, C. A., Corbin, K. D., da Costa, K.-A., Zhang, S., Zhao, X., Galanko, J. A., Blevins, T., Bennett, B. J., O’Connor, A., & Zeisel, S. H. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.087692 · Cited by 240
Sacks, F. M., Carey, V. J., Anderson, C. A. M., Miller, E. R., Copeland, T., Charleston, J., Harshfield, B. J., Laranjo, N., McCarron, P., Swain, J., et al. (2014) · JAMA · doi:10.1001/jama.2014.16658 · Cited by 239 · cited 1×
“S4), in keeping with the recognised effect of carbohydrates on features of atherogenic dyslipidemia, and in overall agreement with the recent OmniCarb study((52)), which found that plasma TAG were increased by higher CHO intake, but were not influenced by starch quality as assessed by the glycaemic index.”
ResultRohrmann, S., Linseisen, J., Allenspach, M., von Eckardstein, A., & Müller, D. (2016) · The Journal of Nutrition · doi:10.3945/jn.115.220103 · Cited by 197
Association between dietary fiber intake and risk of coronary heart disease: A meta-analysis
Wu, Y., Qian, Y., Pan, Y., Li, P., Yang, J., Ye, X., & Xu, G. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2014.05.009 · Cited by 128 · cited 1×
“In light of the health benefits generally ascribed to RS, and of epidemiological evidence linking high fibre intake to reduced CVD risk((58)), the increase in TMAO with RS is contrary to what might be expected.”
ResultProbiotic supplementation and trimethylamine‐N‐oxide production following a high‐fat diet
Boutagy, N. E., Neilson, A. P., Osterberg, K. L., Smithson, A. T., Englund, T. R., Davy, B. M., Hulver, M. W., & Davy, K. P. (2015) · Obesity · doi:10.1002/oby.21212 · Cited by 127
Yadav, B. S., Sharma, A., & Yadav, R. B. (2009) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637480902970975 · Cited by 67
Barton, S., Navarro, S. L., Buas, M. F., Schwarz, Y., Gu, H., Djukovic, D., Raftery, D., Kratz, M., Neuhouser, M. L., & Lampe, J. W. (2015) · Food & Function · doi:10.1039/c5fo00287g · Cited by 55
Cited by
Janeiro, M., Ramírez, M., Milagro, F., Martínez, J., & Solas, M. (2018) · Nutrients · doi:10.3390/nu10101398 · Cited by 631
“Additionally, some studies suggest that a diet high in non-digestible carbohydrates can reduce TMAO formation by remodelling gut microbiota [26] while other studies reports the opposite effect, suggesting that a diet high in non-digestible starch increases plasma TMAO levels in the short term [43] (Table 1).”
BackgroundWang, Z., Bergeron, N., Levison, B. S., Li, X. S., Chiu, S., Jia, X., Koeth, R. A., Li, L., Wu, Y., Tang, W. H. W., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy799 · Cited by 496
Self-citationOhira, H., Tsutsui, W., & Fujioka, Y. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17006 · Cited by 482
Health Benefits of Resistant Starch: A Review of the Literature
Bojarczuk, A., Skąpska, S., Mousavi Khaneghah, A., & Marszałek, K. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105094 · Cited by 372
Kwaifa, I. K., Bahari, H., Yong, Y. K., & Noor, S. M. (2020) · Biomolecules · doi:10.3390/biom10020291 · Cited by 345
Metadata
- Authors
- Bergeron, N., Williams, P. T., Lamendella, R., Faghihnia, N., Grube, A., Li, X., Wang, Z., Knight, R., Jansson, J. K., Hazen, S. L., & Krauss, R. M.
- Venue
- British Journal of Nutrition
- Publisher
- Cambridge University Press (CUP)
- Published
- 2016-12-20
- Volume
- 116
- Issue
- 12
- Pages
- 2020-2029
- ISSN
- 0007-1145 (ISSN-L)
- 1475-2662
- OpenAlex
- W2561168692
- Cited by
- 100
- References
- 26
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.